How to emerge from the conservatism in clinical research methodology?

Document type :

Article dans une revue scientifique: Article de synthèse/Review paper

DOI :

10.1097/CCO.0000000000000399

PMID :

Permalink :

http://hdl.handle.net/20.500.12210/17231

Title :

How to emerge from the conservatism in clinical research methodology?

Author(s) :

Kotecki, Nuria [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Penel, Nicolas [Auteur]

221576|||Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS] (VALID)
Awada, Ahmad [Auteur]
Université libre de Bruxelles [ULB]

Journal title :

Current Opinion in Oncology

Abbreviated title :

Curr. Opin. Oncol.

Volume number :

29

Pages :

400-404

Publisher :

Lippincott, Williams & Wilkins

Publication date :

2017-09-01

ISSN :

1040-8746

English keyword(s) :

solid tumors
innovative approach
new drugs
unmet need
network

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

OBJECTIVE: Despite recent changes in clinical research methodology, many challenges remain in drug development methodology. RESULTS: Advances in molecular biology and cancer treatments have changed the clinical research ...
Show more >OBJECTIVE: Despite recent changes in clinical research methodology, many challenges remain in drug development methodology. RESULTS: Advances in molecular biology and cancer treatments have changed the clinical research landscape. Thus, we moved from empirical clinical oncology to molecular and immunological therapeutic approaches. Along with this move, adapted dose-limiting toxicities definitions, endpoints, and dose escalation methods have been proposed. Moreover, the classical frontier between phase I, phase II, and phase III has become unclear in particular for immunological approaches. So, investigators are facing major challenges in drug development methodology. CONCLUSIONS: We propose to individualize clinical research using innovative approaches to significantly improve patient outcomes and targeting what is considered unmet need. Integrating high level of translational research and performing well designed biomarker studies with great potential for clinical practice are of utmost importance. This could be performed within new models of clinical research networks and by building a strong collaboration between academic, cooperative groups, on-site investigators, and pharma.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
Université de Lille

Collections :

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694

Submission date :

2019-12-09T18:17:04Z
2024-12-18T10:45:59Z

Version history